AEGR and RGEN MAA filings. XOMA offering. ANTH ZLCS update

Mar 06, 2012 No Comments by

Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for lomitapide to reduce cholesterol in patients with Homozygous Familial Hypercholesterolemia (HoFH).

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) said its Phase 2b PEARL-SC trial  in pateints with systemic lupus erythematosus will continue following an interim analysis of all safety and efficacy data. Top-line efficacy data are expected in 2Q 2012.

Zalicus Inc. (NASDAQ: ZLCS) said that it intends to initiate a Phase 2 trial of  Z160 for the treatment of neuropathic pain in 2H 2012.

XOMA Corporation (Nasdaq:XOMA) announced today that it is offering to sell shares of its common stock and corresponding warrants to purchase one half of a share of common stock for each share purchased.

Repligen Corporation (NASDAQ:RGEN) announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for SecreFlo™ to improve detection of pancreatic duct abnormalities in patients with pancreatitis.

Daily News

About the author

Currently residing in New Zealand and employed in the education industry, Mr. A. Burden holds a M.Com in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.
No Responses to “AEGR and RGEN MAA filings. XOMA offering. ANTH ZLCS update”

Leave a Reply